Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) receives CHMP positive opinion for expanded use in children and adolescents with growth hormone deficiency

Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases